Shanghai Fosun Omni Pharma Execs On China Following A Different Pharma Model Than India: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a JV between two former principal R&D leaders from Ivax/Tevaand Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and COO Shaochuan Zeng, the two former leaders from Ivax/Teva, spoke with PharmAsia News about their operation and Chinese pharmas going international.
You may also be interested in...
With Two Deals In Place, Amerigen Looks To Leverage China For Branded Generics
U.S. startup looks to tap into China’s generic market – both in China and back home in the states.
Shanghai Fosun Omni Pharma Execs On The Market For Inhalation Products In China: An Interview With PharmAsia News (Part 2 of 2)
Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a joint venture between two former principal R&D leaders from Ivax/Teva and Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and Chief Operating Officer Shaochuan Zeng, the former leaders from Ivax/Teva, spoke with PharmAsia News' Shanghai bureau about their operation and the market for inhalation products in China.
Shanghai Fosun Omni Pharma Execs On The Market For Inhalation Products In China: An Interview With PharmAsia News (Part 2 of 2)
Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a joint venture between two former principal R&D leaders from Ivax/Teva and Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and Chief Operating Officer Shaochuan Zeng, the former leaders from Ivax/Teva, spoke with PharmAsia News' Shanghai bureau about their operation and the market for inhalation products in China.